Clinical Trials

Beyond First Line Therapy

A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors

LEARN MORE

Beyond First Line Therapy

Phase IIb trial of pemigatinib in combination with atezolizumab and bevacizumab for treatment of advanced cholangiocarcinoma with FGFR2 fusion

LEARN MORE

Beyond First Line Therapy

Alliance EAY191-A6: A ComboMATCH Treatment Trial: FOLFOX in Combination with Binimetinib as 2nd Line Therapy for Patients with Advanced Biliary Tract Cancers with MAPK Pathway Alterations

LEARN MORE

Beyond First Line Therapy

GNS561-221-1

LEARN MORE

Beyond First Line Therapy

A Phase Ia/Ib Study of the Combination of the FGFR inhibitor Pemigatinib and the EGFR inhibitor Afatinib in Advanced Refractory Solid Tumors

LEARN MORE

Beyond First Line Therapy

A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33-hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination with Pembrolizumab in Adult Patients with Metastatic or Advanced Solid Tumors (MAST).

LEARN MORE

Beyond First Line Therapy

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

LEARN MORE

Beyond First Line Therapy

NCI/CTEP 10276: A Phase 1/2 Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

LEARN MORE

Beyond First Line Therapy

A Phase 2 study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

LEARN MORE

Beyond First Line Therapy

A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination with Paclitaxel Versus Paclitaxel Alone in Adult Patients with Unresectable, Advanced, Metastatic or Recurrent Biliary Tract Cancers Who Have Received One Prior Systemic Chemotherapy Regimen - COMPANION-002

LEARN MORE

Beyond First Line Therapy

A Study to Evaluate KIN-3248 (study drug) in Patients with Advanced Tumors Who Have FGFR2 and//or FGFR3 Gene Alterations

LEARN MORE

Beyond First Line Therapy

Safety and Tolerability of TNG908 in Patients with MTAP-deleted Solid Tumors

LEARN MORE